Indalpine

DB08953

small molecule investigational withdrawn

Deskripsi

Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

Struktur Molekul 2D

Berat 228.3327
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1635 Data
Cyproheptadine The therapeutic efficacy of Indalpine can be decreased when used in combination with Cyproheptadine.
Desmopressin The risk or severity of hyponatremia can be increased when Indalpine is combined with Desmopressin.
Ioflupane I-123 Indalpine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Indalpine.
Metyrosine The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Indalpine.
Pimozide The risk or severity of QTc prolongation can be increased when Indalpine is combined with Pimozide.
Buprenorphine Indalpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Indalpine.
Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Indalpine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Indalpine.
Hydrocodone Indalpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Indalpine.
Magnesium sulfate The therapeutic efficacy of Indalpine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Indalpine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Indalpine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Indalpine.
Orphenadrine Indalpine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Indalpine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Indalpine.
Pramipexole Indalpine may increase the sedative activities of Pramipexole.
Ropinirole Indalpine may increase the sedative activities of Ropinirole.
Rotigotine Indalpine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Indalpine.
Sodium oxybate Indalpine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Indalpine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Indalpine.
Thalidomide Indalpine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Indalpine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Indalpine.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Indalpine.
Everolimus The metabolism of Everolimus can be decreased when combined with Indalpine.
Flibanserin The metabolism of Flibanserin can be decreased when combined with Indalpine.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Indalpine.
Ivabradine The metabolism of Ivabradine can be decreased when combined with Indalpine.
Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Indalpine.
Lurasidone The metabolism of Lurasidone can be decreased when combined with Indalpine.
Naloxegol The metabolism of Naloxegol can be decreased when combined with Indalpine.
Olaparib The metabolism of Olaparib can be decreased when combined with Indalpine.
Ranolazine The metabolism of Ranolazine can be decreased when combined with Indalpine.
Sonidegib The metabolism of Sonidegib can be decreased when combined with Indalpine.
Avanafil The metabolism of Avanafil can be decreased when combined with Indalpine.
Eplerenone The metabolism of Eplerenone can be decreased when combined with Indalpine.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Indalpine.
Colchicine The metabolism of Colchicine can be decreased when combined with Indalpine.
Fentanyl The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Indalpine.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Indalpine.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Indalpine.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Indalpine.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Indalpine.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Indalpine.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Indalpine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Indalpine.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Indalpine.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Indalpine.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Indalpine.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Indalpine.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Indalpine.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Indalpine.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Indalpine.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Indalpine.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Indalpine.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Indalpine.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Indalpine.
Tedizolid phosphate The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Indalpine.
Mirtazapine Indalpine may increase the serotonergic activities of Mirtazapine.
Morphine The risk or severity of serotonin syndrome can be increased when Morphine is combined with Indalpine.
Codeine The risk or severity of serotonin syndrome can be increased when Codeine is combined with Indalpine.
Hydromorphone The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Indalpine.
Oxycodone The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Indalpine.
Butorphanol The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Indalpine.
Dextropropoxyphene The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Indalpine.
Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Indalpine.
Sufentanil The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Indalpine.
Nalbuphine The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Indalpine.
Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Indalpine.
Remifentanil The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Indalpine.
Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Indalpine.
Oxymorphone The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Indalpine.
Dezocine The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Indalpine.
Methadyl acetate The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Indalpine.
Dihydroetorphine The risk or severity of serotonin syndrome can be increased when Dihydroetorphine is combined with Indalpine.
Diamorphine The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Indalpine.
Ethylmorphine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Indalpine.
Etorphine The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Indalpine.
Dextromoramide The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Indalpine.
Desomorphine The risk or severity of serotonin syndrome can be increased when Desomorphine is combined with Indalpine.
Carfentanil The risk or severity of serotonin syndrome can be increased when Carfentanil is combined with Indalpine.
Dihydrocodeine The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Indalpine.
Alphacetylmethadol The risk or severity of serotonin syndrome can be increased when Alphacetylmethadol is combined with Indalpine.
Dihydromorphine The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Indalpine.
Ketobemidone The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Indalpine.
DPDPE The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Indalpine.
Lofentanil The risk or severity of serotonin syndrome can be increased when Lofentanil is combined with Indalpine.
Opium The risk or severity of serotonin syndrome can be increased when Opium is combined with Indalpine.
Normethadone The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Indalpine.
Piritramide The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Indalpine.
Alphaprodine The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Indalpine.
Meptazinol The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Indalpine.
Phenoperidine The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Indalpine.
Phenazocine The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Indalpine.

Referensi & Sumber

Synthesis reference: U.S. Patent 4,064,255.
Artikel (PubMed)
  • PMID: 20034793
    Marcin LR, Mattson RJ, Gao Q, Wu D, Molski TF, Mattson GK, Lodge NJ: Synthesis and hSERT activity of homotryptamine analogs. Part 6: 3+2 dipolar cycloaddition of 3-vinylindoles. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1027-30. doi: 10.1016/j.bmcl.2009.12.043. Epub 2009 Dec 16.
  • PMID: 3058454
    Galbaud du Fort G: Hematologic toxicity of antidepressive agents. Encephale. 1988 Jul-Aug;14(4):307-18.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Upstène — Pharmuka

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul